AN2 Therapeutics, Inc., (ANTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANTX Stock Price Chart Interactive Chart >
ANTX Price/Volume Stats
| Current price | $9.64 | 52-week high | $23.58 |
| Prev. close | $9.95 | 52-week low | $6.88 |
| Day low | $9.35 | Volume | 38,000 |
| Day high | $10.21 | Avg. volume | 54,921 |
| 50-day MA | $15.08 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 187.04M |
AN2 Therapeutics, Inc., (ANTX) Company Bio
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Latest ANTX News From Around the Web
Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.
Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Halozyme (HALO)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AstraZeneca (AZN – Research Report), Halozyme (HALO – Research Report) and AN2 Therapeutics, Inc. (ANTX – Research Report) with bullish sentiments. AstraZeneca (AZN) In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on AstraZeneca, with a price target of $79.00. The company's shares closed last Friday at $62.77. According to TipRanks. |
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesU.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in TrialAwarded Contract from NIAID Valued Up to $17.8 Million to Advance Development of Epetraborole for Acute Systemic Melioidosis MENLO PARK, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infecti |
AN2 Therapeutics to Present at Upcoming Investor ConferencesMENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Details of the events are as follows: Stifel 2022 Healthcare Conference, November 15-17, 2022, New York, New York. Eric Easom, Co-Founder, President a |
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from |
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung DiseaseEpetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese PatientsTreatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung DiseaseEpetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical- |
ANTX Price Returns
| 1-mo | -39.52% |
| 3-mo | -24.57% |
| 6-mo | -26.97% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...